Nilotinib (hydrochloride dihydrate)
Nilotinib (AMN107) hydrochloride dihydrate is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia[1][2][3].
Product Specifications
Product Name Alternative
AMN107 (hydrochloride dihydrate)
UNSPSC
12352005
Target
Autophagy; Bcr-Abl
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(N2C=NC(C)=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3.O.O.Cl
Molecular Formula
C28H27ClF3N7O3
Molecular Weight
602.01
References & Citations
[1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109 (5) :2112-20.|[2]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9 (9) :e107613.|[3]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC422938 20 µg
RNS10 (RNASE10) (NM_001012975) Human Over-expression Lysate
Sign In for Pricing
View Details 
